Last reviewed 2026-04-19 · How we verify

Drug: LW402

Shanghai Longwood Biopharmaceuticals Co., Ltd. · Phase 2 active Small molecule

Drug: LW402 is a Small molecule drug developed by Shanghai Longwood Biopharmaceuticals Co., Ltd.. It is currently in Phase 2 development.

At a glance

Generic name	Drug: LW402
Sponsor	Shanghai Longwood Biopharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Drug: LW402 CI brief — competitive landscape report
Drug: LW402 updates RSS · CI watch RSS
Shanghai Longwood Biopharmaceuticals Co., Ltd. portfolio CI

Frequently asked questions about Drug: LW402

What is Drug: LW402?

Drug: LW402 is a Small molecule drug developed by Shanghai Longwood Biopharmaceuticals Co., Ltd..

Who makes Drug: LW402?

Drug: LW402 is developed by Shanghai Longwood Biopharmaceuticals Co., Ltd. (see full Shanghai Longwood Biopharmaceuticals Co., Ltd. pipeline at /company/shanghai-longwood-biopharmaceuticals-co-ltd).

What development phase is Drug: LW402 in?

Drug: LW402 is in Phase 2.

Manufacturer: Shanghai Longwood Biopharmaceuticals Co., Ltd. — full pipeline
Compare: Drug: LW402 vs similar drugs
Pricing: Drug: LW402 cost, discount & access